Equities
Health CareMedical Equipment and Services
  • Price (USD)43.23
  • Today's Change-0.82 / -1.86%
  • Shares traded933.45k
  • 1 Year change+10.21%
  • Beta0.3535
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

  • Revenue in USD (TTM)1.94bn
  • Net income in USD72.70m
  • Incorporated1996
  • Employees5.90k
  • Location
    Qiagen NVHulsterweg 82VENLO 5912 PLNetherlandsNLD
  • Phone+31 773556600
  • Fax+31 773208409
  • Websitehttps://www.qiagen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cytokinetics, Inc.3.22m-576.40m6.90bn423.00------2,142.65-5.39-5.390.0301-0.1180.003--2.357,609.93-52.96-43.14-57.95-47.22-----17,906.24-540.47---14.271.02---92.04-24.89-35.30--9.76--
Viking Therapeutics Inc0.00-99.15m7.02bn33.00--7.70-----0.937-0.9370.008.180.00----0.00-15.02-21.91-15.47-23.04------------0.00-------24.73------
Legend Biotech Corp (ADR)455.99m-285.01m7.38bn2.20k--6.33--16.18-1.57-1.572.516.330.244610.6332.42253,328.30-15.29-37.71-17.63-47.1960.28---62.50-286.514.78--0.2263--143.7042.15-16.11--1.57--
Madrigal Pharmaceuticals Inc76.81m-518.67m7.41bn376.00--9.53--96.44-25.07-25.073.7135.640.1172----204,289.90-79.11-62.09-100.35-74.8196.37---675.24--5.93--0.1309-------26.50--132.01--
Exact Sciences Corp2.69bn-214.04m9.50bn6.50k--2.965,211.173.53-1.17-1.1714.7017.350.40895.4011.60414,204.30-3.25-9.71-3.58-10.6072.9674.10-7.95-28.211.93--0.4459--19.9340.6367.26---3.71--
Qiagen NV1.94bn72.70m9.86bn5.90k138.442.8734.915.080.31820.31828.6915.320.32522.015.57325,154.801.225.411.476.5363.0364.653.7516.351.46--0.2916---8.235.53-19.3512.381.55--
Revolution Medicines Inc742.00k-567.06m10.19bn490.00--6.49--13,738.67-3.59-3.590.00479.340.0005--4.801,962.96-41.28-29.76-44.46-32.59-----76,423.31-606.93----0.00---67.27-10.50-75.46--38.82--
Exelixis Inc2.08bn466.92m10.34bn1.31k23.064.5520.904.961.571.576.927.960.70123.398.041,589,006.0015.738.8618.089.9196.2596.3022.4315.433.88--0.000.0013.6016.4713.98-21.343.98--
Sarepta Therapeutics Inc1.64bn121.85m11.26bn1.31k96.909.2270.146.861.221.2216.3012.790.4890.57034.351,248,362.003.63-21.634.38-25.7585.9286.657.43-77.053.03--0.5013--33.2632.8023.81--6.30--
Charles River Lbrtrs ntrntl Inc4.06bn413.08m11.29bn20.00k27.552.9814.692.788.018.0178.6373.970.52038.275.23203,045.805.486.466.337.6235.9336.9910.5411.581.144.960.37840.003.8612.75-2.3916.6917.86--
Medpace Holdings Inc2.07bn365.57m11.30bn5.90k31.8412.7928.655.4611.4211.4264.7028.421.16--6.85350,994.3020.4813.9443.5123.1829.6928.8417.6615.23----0.00--29.1721.7615.2631.1717.99--
BIO-TECHNE Corp1.17bn150.68m11.87bn3.10k79.445.5545.2910.130.94020.94027.2913.460.42672.155.47377,930.005.499.425.7710.0465.9367.2912.8621.413.2618.070.12322.791.9710.17-41.0711.8619.870.00
Tempus AI Inc640.44m-800.71m12.22bn2.30k--224.39--19.08-8.29-8.294.440.3459----------------53.18---116.06--2.55-14.950.891--65.85--20.35------
Insmed Inc342.96m-864.29m12.85bn912.00--26.57--37.46-5.56-5.562.212.700.20310.88488.81376,050.40-51.17-40.96-59.16-46.8877.2577.99-252.01-212.925.99-18.410.6702--24.3998.78-55.66---2.15--
Neurocrine Biosciences, Inc.2.24bn385.90m12.88bn1.70k34.064.7331.285.743.733.7321.6726.870.70270.89014.991,602,000.0012.099.7714.6712.1998.5298.5117.2114.794.2610.280.00--26.7633.1361.6263.902.67--
Data as of Nov 13 2024. Currency figures normalised to Qiagen NV's reporting currency: US Dollar USD

Institutional shareholders

39.94%Per cent of shares held by top holders
HolderShares% Held
Massachusetts Financial Services Co.as of 30 Jun 202423.20m10.46%
Wellington Management Co. LLPas of 30 Sep 202421.25m9.58%
Capital Research & Management Co. (International Investors)as of 30 Jun 20247.46m3.36%
Wellington Management International Ltd.as of 30 Jun 20246.37m2.87%
The Vanguard Group, Inc.as of 30 Jun 20246.16m2.78%
Amundi Asset Management US, Inc.as of 30 Jun 20245.64m2.54%
MFS International (UK) Ltd.as of 30 Sep 20245.11m2.31%
MFS International Singapore Pte Ltd.as of 30 Sep 20244.72m2.13%
Nuance Investments LLCas of 30 Sep 20244.49m2.03%
Norges Bank Investment Managementas of 30 Jun 20244.19m1.89%
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.